Soleno Therapeutics to Participate in the Oppenheimer Rare & Orphan Disease Summit
Soleno Therapeutics, Inc. (NASDAQ: SLNO) will present a corporate overview at the Oppenheimer Rare & Orphan Disease Summit on May 21, 2021, at 1:15 PM ET. CEO Anish Bhatnagar will lead the presentation, highlighting the company's focus on developing novel therapeutics for rare diseases, particularly its lead candidate, DCCR extended-release tablets, aimed at treating Prader-Willi Syndrome (PWS) in Phase 3 clinical trials. A live audio webcast will be available on the company’s website.
- None.
- None.
REDWOOD CITY, Calif., May 20, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will present a corporate overview at the Oppenheimer Rare & Orphan Disease Summit on Friday, May 21, 2021 at 1:15 PM Eastern Time.
A live audio webcast and replay of the presentation will be available in the Investors section on the Company’s website at www.soleno.life.
About Soleno Therapeutics, Inc.
Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company’s lead candidate, DCCR extended-release tablets, a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is currently being evaluated in a Phase 3 clinical development program. For more information, please visit www.soleno.life.
Corporate Contact:
Brian Ritchie
LifeSci Advisors, LLC
212-915-2578
FAQ
When is Soleno Therapeutics presenting at the Oppenheimer Rare & Orphan Disease Summit?
Who will be presenting for Soleno Therapeutics at the summit?
What is the focus of Soleno Therapeutics?
What is Soleno's lead candidate for Prader-Willi Syndrome?
Where can I access the webcast for Soleno's presentation?
